GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » Operating Cash Flow per Share

Vir Biotechnology (Vir Biotechnology) Operating Cash Flow per Share : $-5.68 (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology Operating Cash Flow per Share?

Vir Biotechnology's operating cash flow per share for the three months ended in Mar. 2024 was $-0.81. Vir Biotechnology's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.68.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Vir Biotechnology was -176.30% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -53.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Vir Biotechnology's Operating Cash Flow per Share or its related term are showing as below:

VIR' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -53.6   Med: -32.7   Max: 28.4
Current: -53.6

During the past 7 years, Vir Biotechnology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 28.40% per year. The lowest was -53.60% per year. And the median was -32.70% per year.

VIR's 3-Year OCF Growth Rate is ranked worse than
89.78% of 1233 companies
in the Biotechnology industry
Industry Median: 3.5 vs VIR: -53.60

Vir Biotechnology Operating Cash Flow per Share Historical Data

The historical data trend for Vir Biotechnology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology Operating Cash Flow per Share Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial -4.27 -1.60 -0.36 12.34 -5.81

Vir Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -2.90 -1.16 -0.80 -0.81

Competitive Comparison of Vir Biotechnology's Operating Cash Flow per Share

For the Biotechnology subindustry, Vir Biotechnology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vir Biotechnology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's Price-to-Operating-Cash-Flow falls into.



Vir Biotechnology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Vir Biotechnology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-778.785/134.131
=-5.81

Vir Biotechnology's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-109.39/135.281
=-0.81

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vir Biotechnology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology (Vir Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Executives
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang officer: Chief Medical Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De officer: Chief Executive Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee officer: Chief Financial Officer 7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos director, officer: President and CEO C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn officer: CFO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin officer: EVP, Research & CSO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano director C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001

Vir Biotechnology (Vir Biotechnology) Headlines

From GuruFocus